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on mortality associated to ID and CAP, for the base case scenario. It predicts that
vaccines would reduce 11.34 deaths (PCV-13) and 11.03 deaths (PHiD-CV) per
100,000 vaccinated infants. Besides, PHiD-CV would reduce 221 more myringoto-
mies and 3,891 more AOM cases than PCV-13, per 100,000 vaccinated infants. The
direct medical costs averted (undiscounted) due to ID and CAP is similar for both
vaccines. Instead, PHiD-CV would save 1.9 times more AOM medical costs than
PCV-13. Both vaccines are cost effective, but PHiD-CV would generate more QALY
gains (1176 additional QALYs) and in addition, would be cost saving. It was esti-
mated that PHiD-CV requires a reduced annual investment of 10 million (PAHO
prices) or 1.6 million (price parity) US$, compared to PCV-13. CONCLUSIONS: Both
vaccines would reduce significantly the impact of invasive pneumococcal disease
and CAP, but PHiD-CV will generate more QALYs gain and will be cost saving
compared to PCV-13, due to its greater effects over AOM.
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OBJECTIVES: Despite recent progress in our understanding of the economics of
ADHD in children and adolescents, little is known about the comparative cost
effectiveness of treatment strategies for adult ADHD. Even for ADHD in children,
there is a shortage of robust data supporting the cost effectiveness of psychother-
apeutic interventions.METHODS: A randomized, double-blind, placebo-controlled
multicenter study has been initiated in Germany, enrolling 448 adult patients with
ADHD. Patients are assigned to one out of four parallel treatment arms: 1) a struc-
tured disorder tailored psychotherapy (dialectical behavioral therapy, DBT) plus
medication (methylphenidate); 2) DBT and placebo; 3) psychiatric counseling with-
out specific behavioral interventions (clinical management) plus medication; or 4)
clinical management and placebo. DBT and clinical management are administered
weekly for the first 12 weeks and on a four-weekly basis thereafter, until the end of
the one-year-observation period. An additional follow-up investigation is sched-
uled at 18 months after treatment termination. RESULTS: Endpoints include symp-
tomatic improvement (primary endpoint: Conners’ Adult Rating Scale, blind-ob-
server rated), general psychopathology, clinical global impression, and a disorder-
specific quality of life questionnaire. In order to facilitate cost utility analysis,
health-related quality of life is also measured by means of the EQ-5D and SF-36. For
primary analysis, the perspective of Statutory Health Insurance will be adopted;
resource use and costing from a societal perspective will be done for secondary
analyses. Probabilistic sensitivity analyses will be done using nonparametric boot-
strapping on the basis of patient-level study data. CONCLUSIONS: The COMPAS
Study will, for the first time, provide insights into the cost effectiveness of a disor-
der tailored psychotherapy for adult ADHD. Key hypotheses are: 1) that combined
treatment (study arm 1) is more effective than either option (DBT or medication)
alone, both short and long term, and 2) that a tailored psychotherapeutic interven-
tion will meet broadly accepted benchmarks of cost effectiveness.
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OBJECTIVES:To estimate the cost effectiveness of dienogest versus GnRH analogue
(GnRH-a) for the treatment of endometriosis-associated chronic pelvic pain in Slo-
vakia for 5 years time horizon. METHODS: A cost-utility Markov model based on
results of randomized controlled trial (AU19) was adapted to a Slovakian setting.
The AU19 trial, which compared dienogest and GnRH-a (leuprolide) in the treat-
ment of endometriosis-associated chronic pelvic pain over a 6 month period,
showed no statistically significant differences in response rates. The dienogest
annual relapse rate was derived from 52-weeks extension study, while relapse
rates for the GnRH-a were derived from the literature. Local cost data was based on
published price lists, clinical guidelines, product labels and expert opinion. QoL
related utilities were derived from individual patient SF-36 scores from AU19 da-
taset. Effectiveness was measured in quality-adjusted life years (QALY). Time ho-
rizon was set at five years and a payers’ perspective was adopted. Discount rate was
5% per year for both costs and effects according to valid Ministry of Health (MoH)
guidelines for health economic evaluation. Both one-way and probabilistic sensi-
tivity analyses were performed. RESULTS: Dienogest showed that it was cost-ef-
fective compared to a GnRH-a, with an overall cost reduction of 426 € and a QALY
gain of 0.069 per patient. Cost reduction was due to both the differences in the
average drug cost during the two year period and the average laparoscopy cost. In
probabilistic sensitivity analysis 92 % of simulations were below 18,000 €/QALY,
which is the officially published threshold for willingness to pay in Slovakia. In 79%
of cases dienogest treatment was dominant over GnRH-a. CONCLUSIONS: Dieno-
gest is a cost-effective alternative to GnRH analogue for the treatment of endo-
metriosis-associated chronic pelvic pain in a Slovakian setting in a five-year time
horizon.
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OBJECTIVES: The majority of individuals with chronic hepatitis C virus (HCV) are
adults, and there is much experience in Australia with interferon-based treat-
ments in adults using combination pegylated- interferon and ribavirin treatment.
Pegylated-interferon alfa-2b was first approved for adult use in Australia and for
reimbursement in 2003. It is currently reimbursed for initial treatment, and for a
single retreatment course. Nonetheless, a limited number of children and adoles-
cents in Australia contract the disease. Currently these individuals have no regis-
tered or reimbursed approved therapies available to them. This analysis reports a
cost-effectiveness analysis of a single course of initial pegylated-interferon alfa-2b
therapy in paediatrics with a bodyweight of at least 27 kg, reflecting the lowest
dosage that will be supplied in Australia. METHODS: A cost-utility analysis was
conducted using a lifetime Markov model. Analysis of paediatric treatment versus
no treatment was undertaken to determine the impact expansion of reimburse-
ment would have on the cost-effectiveness of the total population. Data were
sourced from a study assessing sustained virological response, and the literature
reporting the natural history and utility weights regarding HCV. RESULTS: Down-
stream cost-offsets associated with treatment reduce the total incremental cost
from AU$13,208 to AU$4767. These cost-offsets arose from avoidance of down-
stream transitions to more severe and costly states of health. Treatment was also
shown to be associated with improvements in health-related quality of life due to
the downstream avoidance of more serious health states as well as the obvious
improvement in viral clearance. Over the lifetime of a patient, the base case anal-
ysis estimated an improvement of approximately 2.01 QALYs, generating an incre-
mental cost-effectiveness ratio of AU$2373 per QALY. CONCLUSIONS: Expanding
reimbursement to include paediatric treatment of chronic HCV is a highly cost-
effective way to equitably treat chronic HCV, regardless of age.
Individual’s Health – Patient-Reported Outcomes & Preference-Based Studies
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BACKGROUND: Conducting pediatric studies is complex and the most significant
barrier is infant enrollment by parental consent. This obstacle is currently found
both for healthy and sick infants. The reason for the parents’ refusal to consent is
not obvious and may be due to multiple factors. OBJECTIVES: To identify the fac-
tors influencing parents’ decisions to refuse infant participation in pediatric
studies. METHODS: Observational, transversal study carried out by French phar-
macists randomly selected among the 2,090 pharmacies of the In fine PHARMA®
network (representative of French pharmacies in terms of geographic location and
sales). Parents presenting to participating pharmacies were eligible. Data were
collected through questionnaires fulfilled by participating parents. RESULTS:
Twenty-one pharmacists agreed to participate and enrolled 105 participating par-
ents. Among them, 78 (74%) filled out a questionnaire. Participating families had an
average of 2.3 children, 81% were living in an urban environment, and 51% of the
infants were males. Most of the parents (97%) had never enrolled their children in
a study. Main deterrents to parental consent were: they viewed pediatric studies as
risky (35%), they did not want their infant to be treated as an experimental animal
(20%), their infant was not ill (12%), the information provided by the physician was
too confusing and/or complicated (10%). Parents may have been willing to have
their child participate in a study only if the study was evaluating a new drug, their
child’s participation would further medical research (31%), their child suffered
from a severe illness (24%), and they had great confidence in their physician (22%).
CONCLUSIONS: The results of this survey show that the factors negatively influ-
encing parents’ decisions to consent were the perceived risk presented by the
studies, the lack of interest to medical research if their child was not ill, and the lack
of information about the study.
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OBJECTIVES:Medication nonadherence among patients with chronic conditions is
a significant barrier to achieving therapeutic outcomes. The objective of this study
was to identify patient reported factors and reasons associated with medication
nonadherence. METHODS: Online cross-sectional survey of patients taking medi-
cations for seven chronic conditions: asthma/COPD, bipolar depression, cardiovas-
cular disease, diabetes, neuropathic pain, osteoporosis, and rheumatoid arthritis.
The first 50 patients to respond to the survey for each of the seven conditions were
evaluated (total n350). Patients provided demographic information and answered
questions about their drug therapy including knowledge and satisfaction with their
medications, difficulties in taking their medications, and how often they take their
medication as prescribed. Adherence was defined as patients self-reporting that
they always take their medication as prescribed. Nonadherence was defined as
never, sometimes or often take medications as prescribed. Multivariate logistic
regression was performed to identify patient factors and reasons associated with
nonadherence. RESULTS: Among the 350 patients who completed the survey, the
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average age was 54 years (standard deviation  11 years, range 17-85 years) with
the majority being female (78%), white (87%), having a some college education or
more (73%) and having health insurance (87%). Approximately 58% of patients
reported medication nonadherence. No significant differences were observed be-
tween adherent and nonadherent patients with regard to age, sex, race, insurance
status, condition, or number of medications taken. Reasons significantly associ-
ated with nonadherence were forgetting, don’t like to take pills/give injection, cost
of medication, symptoms improved so stopped taking medication, side effects too
severe, and poor knowledgeable about their medications. CONCLUSIONS: Medica-
tion nonadherence is common and patient reported reasons for nonadherence
include motivational factors, lack of understanding or knowledge, and treatment-
related characteristics. Interventions that motivate, educate and individualize
drug therapy according to patients’ preferences and affordability may improve
adherence.
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OBJECTIVES: The EQ-5D has been extensively used to assess health-related quality
of life (HRQoL) and utility across different health condition worldwide. The aim of
this study was to systematically review studies using EQ-5D in the Brazilian
population. METHODS: A structured literature search was conducted using free
text words related to EQ-5D and Brazil in Pubmed and LILACS database. Original
research studies that reported EQ-5D results among Brazilian patients or general
population were included. RESULTS: Of 23 identified papers (Pubmed11, LI-
LACS12, 3 duplicate citations), 4 met the selection criteria, with one study report-
ing evidence on validity for stroke patients (Pinto 2011), one study reporting EQ-5D
responses (index, VAS and self-classification) for caregivers of stroke patients
(Carod-Artal 2009) and two publications of the same SF-6D study for rheumatoid
arthritis (RA) patients in which EQ-5D was used as a comparison measure (Cam-
polina 2009 and 2010). All 3 studies reported EQ-5D index, 2 of them used the UK
tariff and Carod-Artal 2009 did not inform the conversion method. Mean EQ-5D
index scores were 0.65 (SD 0.3) for RA patients and 0.7 (SD 0.2) for caregivers of
stroke patients. The study which applied EQ-5D to stroke patients did not report
the mean scores, only correlation coefficients with stroke severity and impairment
on daily living activities scales. EQ-5D showed good correlation with SF-6D in the
RA study and with NIH Stroke Scale and modified Barthel Index in the stroke study.
Adequate convergent validity between EQ-5D and Zarit Caregiver Burden Interview
was observed among caregivers of stroke patients. CONCLUSIONS: Although the
EQ-5D is the most widely used generic preference-based measure of health-related
quality of life, studies reporting results for Brazilian samples are still scarce. Nor-
mative reference data for the general population are not available in the published
literature which makes interpreting disease-specific scores a complex task.
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OBJECTIVES: Thailand’s top 5 burden of diseases in 2004 (based on the protocol of
global burden of diseases (GBD) 2004) were HIV/AIDS, traffic accident, stroke, dia-
betes mellitus, and liver cancer, accounting for 947, 718, 652, 474, 407 Disability-
Adjusted Life Years(DALYs) per 1000 population, respectively. The technique used
by GBD to calculate the disability weight (DW) is based on an expert panel sum-
mary. However, this study measured DW directly from the patients and compared
the results. METHODS: The cross-sectional observational multicenter hospital
study was conducted in 2008-2009. The 2,695 sampling patients were selected
based on epidemiologic disease data from outpatient, inpatient and primary-care
unit in 5 major regional hospitals throughout Thailand. Selected patients were
allocated in the quota slot and completed the EQ-5D questionnaires with their
capabilities. The EQ-5D states were converted to utility weight (UW) using the Thai
preference method and then changed into DW with linear regression function to
then compare DALYs directly to the GBD result. RESULTS: Of 2695 patients, 56.99%
are male, and the age is between 1 to 100 years old. The quality of life was calcu-
lated to DW with: DW 0.688 (-0.688 x UW). The new DW differs from GBD weight
from -47.21 to 53.27 percent and these changes will affect the YLD and change the
DALYs -2.83 to 4.84%. CONCLUSIONS: The new DW from the diseases and their
complications differ from the GBD weight. This technique has the tendency to
produce more DW that GBD’s. To establish the burden of diseases, we use the
quality of life to reflect the true disability. The limitation that we have to improve is
the way to calculate the disability weight from EQ-5D for the best prediction.
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OBJECTIVES: In economic evaluations of health care interventions, outcomes are
often expressed in terms of Quality-Adjusted Life-Years (QALYs). Deriving QALY
weights, operationalized as preferences for health states, requires important nor-
mative choices. One important choice is the question whose preferences we wish
to capture. Currently, preferences are commonly derived from the general public,
rather than from actual patients. This choice, which has large consequences on
final outcomes of economic evaluations, is increasingly topic of debate. In the
current study, arguments for and against public preferences are discussed and
alternatives are suggested. METHODS: We highlight and critically assess the dif-
ferent viewpoints put forward in the health economic literature regarding the pub-
lic and patient perspective. Patient preferences are considered to reflect true pa-
tient experiences, but are troublesome because preference values elicited from
patients are ‘unusually’ high due to adaptation. Public preferences are argued to be
less sensitive to adaptation, but are troublesome because they do not adequately
forecast experience. RESULTS: The arguments put forward in the literature do not
provide straightforward support for assessing outcomes QALY weights derived the
general public. The exclusion of patient values in public decision-making is not
sufficiently argued. With patient preferences life saving interventions are likely to
become more cost-effective. CONCLUSIONS: Arguments for and against both po-
sitions represent different normative positions regarding the appropriate measure
of outcome in health care decisions. To date, the debate seems to have focused on
the question which of the two would be most appropriate. However, it seems
unclear why such a dichotomy would be necessary or, in fact, useful. Both public
and patient preferences appear to be important sources of information for the
allocation of health care resources in society. Perhaps the question should be how
to intelligently combine the two.
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OBJECTIVES: To assess the health status and health related quality of life among
rural population residing in coastal region of South India. METHODS: Randomly
selected population attending health awareness camp in rural village of South
India were recruited for the study. Kannada version of EQ-5D5L questionnaire was
used to assess the health related quality of life. Both descriptive and VAS scores
were used for assessment. The population recruited was having the age 18 years
and75 years having the family history of either diabetes, CVD or both. RESULTS:
A total of 126 patients were recruited with the meanSD age of 45.9513.44. The
descriptive scores ranging between minimum 1 and maximum 5 for different
health related quality of life indicators were, mobility score 2.110.88 (meanSD),
self-care score 1.550.83, activity score 2.070.94, pain score 2.380.86 and anxiety
score of 1.961.01. Among the different health states, 11,121 health state was
found as more common (mode). The VAS score found to be 67.5614.64.
CONCLUSIONS: There was considerable impact of pain and activity on the health
related quality of life among rural coastal population in south India who had the
family history of diabetes, CVD or both. There is a need to study the risk factors and
other quality of life indicators among the rural costal population in India.
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OBJECTIVES: Estrogen plus progestin therapies (EPT) represent the current stan-
dard of care for postmenopausal women with a uterus for the treatment of symp-
toms associated with menopause. While successfully treating climacteric symp-
toms, the presence of progestin is necessary to prevent endometrial proliferation.
Progestins contained in EPT are associated with side effects such as breast pain/
tenderness and vaginal spotting/bleeding. The objective of this study was to con-
duct qualitative interviews with menopausal women to better understand the pa-
tient experience of breast pain and vaginal bleeding symptoms associated with
EPT, and the language patients use to describe them, to inform the development of
new measurement tools for these symptoms. METHODS: Fifty-nine postmeno-
pausal women in the USA (n14), China (n15), Mexico (n15) and Italy (n15)
(aged 40-63) taking EPT and experiencing breast pain and/or vaginal bleeding/spot-
ting (47/59 were experiencing both) participated in in-depth interviews concerning
their experiences of EPT and impact on quality of life. Thematic analysis was con-
ducted to identify concepts describing the experiences of the participants using
Atlas Ti. RESULTS: In all 4 countries, breast sensations experienced while taking
EPT were described as ‘pain and tenderness’, ‘feeling swollen’ and ‘sensitivity’ to
touch or contact. Vaginal bleeding and spotting were commonly described in terms
of frequency, volume, colour and consistency. Frequency of both symptoms ranged
from ‘daily’ to ‘occasionally’. Both symptoms impacted on psychological well-be-
ing, activities of daily living and sex life. Items for new measurement tools were
developed using this qualitative data with clinical input from experts in
menopause. CONCLUSIONS: In-depth interviews with a geographically diverse
sample elicited common descriptors for the symptoms of breast pain and vaginal
bleeding and allowed items to be developed that are applicable across cultures,
conceptually consistent and easily translated. Accurately capturing descriptors
used by patients is critical to ensure new outcome tools have content validity and
cross-cultural reliability.
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